HAR THAN



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/071411	
11	NFORMATIO	N DISC	CLOSURE	Filing Date	February 7, 2002	
STATEMENT BY APPLICANT				First Named Inventor	Barnes, Glenn	
				Art Unit	1637	
İ	(Use as many s	sheets as ne	cessary)	Examiner Name	Wilder, Cynthia B.	
Sheet	2	of	3	Attorney Docket Number	MRI-021	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
(W)	B1	Hoshiko, S. et al. "Characterization of the human 5-lipoxygenase gene promoter." <i>Proc. Natl. Acad. Sci. USA</i> 87(23):9073-7 (1990).					
SA	22	In, K.H. et al. "Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription." J. Clin. Invest. 99(5):1130-7 (1997)					
S	В3	Israel, E. et al. "The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma." Annals of Internal Medicine 119(11):1059-66 (1993).					
3	B4	Jatakanon, A. et al. "Changes in sputum eosinophils predict loss of asthma control." Am. J. Respir. Crit. Care Med. 161(1):64-72 (2000).					
K	₿5	Khachigian, L.M. et al. "Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells." The Journal of Biological Chemistry 270(46):27679-86 (1995).					
CW	B6	Li, L. et al. "Positive regulation of human o1 (I) collagen promoter activity by transcription factor Sp1." Gene 164(2):229-34 (1995).					
\mathcal{C}	В7	Lönnkvist, K. et al. "Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal." J. Allergy Clin. Immunol. 107(5):812-7 (2001).					
CW	B8	Matsumoto, T. et al. "Molecular cloning and amino acid sequence of human 5-lipoxygenase." Proc. Natl. Acad. Sci. USA 85(1):26-30 (1988).					
CW	B9	Matsumoto, T. et al. "Correction to Proc. Natl. Acad. Sci. USA 85(1):26-30 (1988)." Proc. Natl. Acad. Sci. USA 85(10):3406 (1988).					
SW	B10	Moffitt, J.E. et al. "Management of asthma in children." American Family Physician 50(5):1039-50, 1053-5 (1994).					
	\B11	O'Byrne, P.M. "Leukotrienes in the pathogenesis of asthma." Chest 111(2 Suppl):27S-34S (1997).					
CN	B12	Persson, M.G. et al. "Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits." <i>Anesthesiology</i> 82(4):969-74 (1995).					
CW	B13	Powell, W.S. et al. "Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis." J. Allergy Clin. Immunol. 107(2):272-8 (2001).	<u> </u>				
CN	B14	Samuelsson, B. "Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation." 220(4597):568-75 Science (1983).					
CM	B15	Samuelsson, B. et al. "Leukotrienes and lipoxins: structures, biosynthesis, and biological effects." Science 237(4819):1171-6 (1987). eference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and reference considered.					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

	110 :	Δ		
Examiner Signature	when	malaler,	Date Considered	5/18/2004
	7			